RT Journal Article
SR Electronic
T1 Antibodies elicited by SARS-CoV-2 infection and boosted by vaccination neutralize an emerging variant and SARS-CoV-1
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.05.21251182
DO 10.1101/2021.02.05.21251182
A1 Stamatatos, Leonidas
A1 Czartoski, Julie
A1 Wan, Yu-Hsin
A1 Homad, Leah J.
A1 Rubin, Vanessa
A1 Glantz, Hayley
A1 Neradilek, Moni
A1 Seydoux, Emilie
A1 Jennewein, Maedeline F.
A1 MacCamy, Anna J.
A1 Feng, Junli
A1 Mize, Gregory
A1 De Rosa, Stephen C.
A1 Finzi, Andrés
A1 Lemos, Maria
A1 Cohen, Kristen W.
A1 Moodie, Zoe
A1 McElrath, M. Juliana
A1 McGuire, Andrew T.
YR 2021
UL http://medrxiv.org/content/early/2021/02/08/2021.02.05.21251182.abstract
AB The emergence of SARS-CoV-2 variants raises concerns about their resistance to neutralizing antibodies elicited from previous infection, or from vaccination. Here we examined whether sera and monoclonal antibodies from convalescent donors, prior to and following a single immunization with the Pfizer or Moderna mRNA vaccines, neutralize the Wuhan-Hu-1 strain and a variant, B.1.351 from South Africa. Pre-vaccination sera weakly neutralized Wuhan-Hu-1 and sporadically neutralized B.1.351. Immunization with either vaccine generated anamnestic B and CD4+ T cell responses and a 1000-fold increase in neutralizing antibody titers against both strains and SARS-CoV-1. Neutralization was likely due to anti-RBD and anti-S2 antibodies. Our study highlights the importance of vaccination of both uninfected and of previously infected subjects, as the elicited immune response will neutralize distinct viral strains.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by generous donations to Fred Hutch COVID-19 Research Fund, and to MJM from the Paul G. Allen Family Foundation, the Joel D. Meyers Endowed Chair, and NIAID UM1 AI068618-14S1, 2UM1 AI069481-15, and UM1A057266-S1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Peripheral blood mononuclear cells (PBMCs) and serum were collected from donors who recovered from SARS-CoV-2 infection and were the first 10 who then subsequently received a SARS-CoV-2 vaccine as part of the study: Seattle COVID-19 Cohort Study to Evaluate Immune Responses in Persons at Risk and with SARS-CoV-2 Infection. Serum from pre-pandemic controls were blindly selected at random from the study: Establishing Immunologic Assays for Determining HIV-1 Prevention and Control, with no considerations made for age, or sex. Both studies were recruited at the Seattle HIV Vaccine Trials Unit (Seattle, Washington, USA). Informed consent was obtained from all participants and the Fred Hutchinson Cancer Research Center Institutional Review Board approved the studies and procedures (IR10440 and IR5567).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is provided in the manuscript.